SNDL（SNDL）株式概要SNDL Inc.はカナダで大麻製品の製造、流通、販売に従事している。 詳細SNDL ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6報酬過去5年間の収益は年間28.6%増加しました。 同業他社や業界と比較して、良好な取引価格 リスク分析現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るSNDL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$2.0179.0% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-331m1b2016201920222025202620282031Revenue CA$1.1bEarnings CA$166.2mAdvancedSet Fair ValueView all narrativesSNDL Inc. 競合他社Verano HoldingsSymbol: NEOE:VRNOMarket cap: CA$583.0mCresco LabsSymbol: CNSX:CLMarket cap: CA$540.4mCanopy GrowthSymbol: TSX:WEEDMarket cap: CA$556.0mTerrAscendSymbol: TSX:TSNDMarket cap: CA$328.3m価格と性能株価の高値、安値、推移の概要SNDL過去の株価現在の株価US$2.0152週高値US$4.0352週安値US$1.60ベータ0.881ヶ月の変化-3.83%3ヶ月変化-6.07%1年変化9.84%3年間の変化n/a5年間の変化n/aIPOからの変化12.29%最新ニュースRecent Insider Transactions • May 03Independent Non-Executive Chairman recently bought CA$95k worth of stockOn the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026お知らせ • Mar 31SNDL Inc. Announces Executive Changes for Cannabis SegmentSNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years).New Risk • Mar 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.最新情報をもっと見るRecent updatesRecent Insider Transactions • May 03Independent Non-Executive Chairman recently bought CA$95k worth of stockOn the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026お知らせ • Mar 31SNDL Inc. Announces Executive Changes for Cannabis SegmentSNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years).New Risk • Mar 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 13Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024)Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Feb 20SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director James Cannell was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 22SNDL Inc. (NasdaqCM:SNDL) announces an Equity Buyback for 24,500,000 shares, for CAD 100 million.SNDL Inc. (NasdaqCM:SNDL) announces a share repurchase program. Under the program, the company will repurchase up to 24,500,000 common shares, representing 10% of its issued share capital for CAD 100 million. The purpose of the program is opportunistically return value to shareholders. All shares purchased pursuant to the Share Repurchase Program will be returned to treasury for cancellation. The program is valid till November 20, 2026.New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$92m Forecast net loss in 1 year: CA$3.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Recent Insider Transactions • Nov 10Independent Non-Executive Chairman recently bought CA$72k worth of stockOn the 6th of November, J. Mills bought around 40k shares on-market at roughly CA$1.79 per share. This transaction increased J.'s direct individual holding by 40000x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was J.'s only on-market trade for the last 12 months.Reported Earnings • Nov 04Third quarter 2025 earnings released: CA$0.05 loss per share (vs CA$0.073 loss in 3Q 2024)Third quarter 2025 results: CA$0.05 loss per share (improved from CA$0.073 loss in 3Q 2024). Revenue: CA$244.2m (up 3.1% from 3Q 2024). Net loss: CA$13.3m (loss narrowed 31% from 3Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Oct 16SNDL Inc. to Report Q3, 2025 Results on Nov 04, 2025SNDL Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: CA$0.01 (vs CA$0.022 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0.01 (up from CA$0.022 loss in 2Q 2024). Revenue: CA$244.8m (up 7.3% from 2Q 2024). Net income: CA$2.89m (up CA$8.66m from 2Q 2024). Profit margin: 1.2% (up from net loss in 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Jul 11SNDL Inc. to Report Q2, 2025 Results on Jul 31, 2025SNDL Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025お知らせ • Jun 23SNDL Inc., Annual General Meeting, Jul 29, 2025SNDL Inc., Annual General Meeting, Jul 29, 2025.New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$107m Forecast net loss in 1 year: CA$9.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$9.5m net loss next year).Reported Earnings • May 02First quarter 2025 earnings released: CA$0.06 loss per share (vs CA$0.01 loss in 1Q 2024)First quarter 2025 results: CA$0.06 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Revenue: CA$204.9m (up 3.6% from 1Q 2024). Net loss: CA$14.7m (loss widened 476% from 1Q 2024). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Apr 15SNDL Inc. to Report Q1, 2025 Results on May 01, 2025SNDL Inc. announced that they will report Q1, 2025 results Pre-Market on May 01, 2025株主還元SNDLCA PharmaceuticalsCA 市場7D3.6%3.0%2.5%1Y9.8%46.0%33.9%株主還元を見る業界別リターン: SNDL過去 1 年間で46 % の収益を上げたCanadian Pharmaceuticals業界を下回りました。リターン対市場: SNDLは、過去 1 年間で33.9 % のリターンを上げたCanadian市場を下回りました。価格変動Is SNDL's price volatile compared to industry and market?SNDL volatilitySNDL Average Weekly Movement7.6%Pharmaceuticals Industry Average Movement11.6%Market Average Movement10.2%10% most volatile stocks in CA Market17.7%10% least volatile stocks in CA Market3.9%安定した株価: SNDL 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: SNDLの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20062,751Zach Georgewww.sndl.comSNDL Inc.はカナダで大麻製品の生産、流通、販売に従事している。同社は4つのセグメントを通じて事業を展開している：酒類小売、大麻小売、大麻事業、投資。成人用・医療用大麻の栽培・流通・販売、ワイン・アンド・ビヨンド、エース・リカー、リカー・デポの各酒販店を通じてのワイン・ビール・蒸留酒の販売、自社およびフランチャイズの大麻小売店を通じての成人用大麻製品・付属品の個人販売などを行っている。また、フラワー、プレロール、VAPEの製造・販売、金融サービスも提供している。Top Leaf、Contraband、Palmetto、Bon Jak、La Logue、Versus、Grasslands、Pearls by Grön、No Future、Bhang Chocolateのブランドで製品を提供している。同社は以前Sundial Growers Inc.として知られていたが、2022年7月にSNDL Inc.に社名を変更した。SNDL社は2006年に法人化され、カナダのカルガリーに本社を置いている。もっと見るSNDL Inc. 基礎のまとめSNDL の収益と売上を時価総額と比較するとどうか。SNDL 基礎統計学時価総額CA$520.86m収益（TTM）-CA$10.98m売上高(TTM)CA$937.39m0.6xP/Sレシオ-47.4xPER（株価収益率SNDL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SNDL 損益計算書（TTM）収益CA$937.39m売上原価CA$682.57m売上総利益CA$254.82mその他の費用CA$265.80m収益-CA$10.98m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.042グロス・マージン27.18%純利益率-1.17%有利子負債／自己資本比率0%SNDL の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 13:19終値2026/05/25 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SNDL Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Aaron GreyAlliance Global PartnersFrederico Yokota Choucair GomesATB CormarkDavid KideckelATB Cormark6 その他のアナリストを表示
Recent Insider Transactions • May 03Independent Non-Executive Chairman recently bought CA$95k worth of stockOn the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.
Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026
お知らせ • Mar 31SNDL Inc. Announces Executive Changes for Cannabis SegmentSNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.
New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years).
New Risk • Mar 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Recent Insider Transactions • May 03Independent Non-Executive Chairman recently bought CA$95k worth of stockOn the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares.
Reported Earnings • May 01First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025)First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Apr 16SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026
お知らせ • Mar 31SNDL Inc. Announces Executive Changes for Cannabis SegmentSNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours.
New Risk • Mar 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years).
New Risk • Mar 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 13Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024)Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Feb 20SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026
Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director James Cannell was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 22SNDL Inc. (NasdaqCM:SNDL) announces an Equity Buyback for 24,500,000 shares, for CAD 100 million.SNDL Inc. (NasdaqCM:SNDL) announces a share repurchase program. Under the program, the company will repurchase up to 24,500,000 common shares, representing 10% of its issued share capital for CAD 100 million. The purpose of the program is opportunistically return value to shareholders. All shares purchased pursuant to the Share Repurchase Program will be returned to treasury for cancellation. The program is valid till November 20, 2026.
New Risk • Nov 17New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$92m Forecast net loss in 1 year: CA$3.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Recent Insider Transactions • Nov 10Independent Non-Executive Chairman recently bought CA$72k worth of stockOn the 6th of November, J. Mills bought around 40k shares on-market at roughly CA$1.79 per share. This transaction increased J.'s direct individual holding by 40000x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was J.'s only on-market trade for the last 12 months.
Reported Earnings • Nov 04Third quarter 2025 earnings released: CA$0.05 loss per share (vs CA$0.073 loss in 3Q 2024)Third quarter 2025 results: CA$0.05 loss per share (improved from CA$0.073 loss in 3Q 2024). Revenue: CA$244.2m (up 3.1% from 3Q 2024). Net loss: CA$13.3m (loss narrowed 31% from 3Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Oct 16SNDL Inc. to Report Q3, 2025 Results on Nov 04, 2025SNDL Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025
Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: CA$0.01 (vs CA$0.022 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0.01 (up from CA$0.022 loss in 2Q 2024). Revenue: CA$244.8m (up 7.3% from 2Q 2024). Net income: CA$2.89m (up CA$8.66m from 2Q 2024). Profit margin: 1.2% (up from net loss in 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Jul 11SNDL Inc. to Report Q2, 2025 Results on Jul 31, 2025SNDL Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025
お知らせ • Jun 23SNDL Inc., Annual General Meeting, Jul 29, 2025SNDL Inc., Annual General Meeting, Jul 29, 2025.
New Risk • May 14New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$107m Forecast net loss in 1 year: CA$9.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$9.5m net loss next year).
Reported Earnings • May 02First quarter 2025 earnings released: CA$0.06 loss per share (vs CA$0.01 loss in 1Q 2024)First quarter 2025 results: CA$0.06 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Revenue: CA$204.9m (up 3.6% from 1Q 2024). Net loss: CA$14.7m (loss widened 476% from 1Q 2024). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Apr 15SNDL Inc. to Report Q1, 2025 Results on May 01, 2025SNDL Inc. announced that they will report Q1, 2025 results Pre-Market on May 01, 2025
